Shares of Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) have earned an average recommendation of “Buy” from the five research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $17.33.
Several research firms recently issued reports on TRHC. Piper Jaffray Companies increased their price target on shares of Tabula Rasa Healthcare from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 14th. Stifel Nicolaus increased their price target on shares of Tabula Rasa Healthcare from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, March 14th. Finally, Zacks Investment Research lowered shares of Tabula Rasa Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, March 25th.
COPYRIGHT VIOLATION WARNING: This article was first published by sleekmoney and is owned by of sleekmoney. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://sleekmoney.com/tabula-rasa-healthcare-inc-trhc-receives-17-33-average-price-target-from-analysts/1916625.html.
In related news, Director Glen R. Bressner acquired 7,500 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was acquired at an average price of $11.96 per share, with a total value of $89,700.00. Following the purchase, the director now directly owns 18,256 shares in the company, valued at $218,341.76. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Orsula V. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $14.02, for a total transaction of $112,160.00. The disclosure for this sale can be found here. Insiders have sold a total of 38,759 shares of company stock worth $520,844 in the last quarter. 45.80% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of the stock. TIAA CREF Investment Management LLC increased its position in shares of Tabula Rasa Healthcare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after buying an additional 4,232 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Tabula Rasa Healthcare by 54.4% in the first quarter. Geode Capital Management LLC now owns 32,209 shares of the company’s stock valued at $434,000 after buying an additional 11,349 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Tabula Rasa Healthcare during the first quarter valued at approximately $178,000. Vanguard Group Inc. increased its position in shares of Tabula Rasa Healthcare by 22.7% in the first quarter. Vanguard Group Inc. now owns 208,967 shares of the company’s stock valued at $2,817,000 after buying an additional 38,720 shares during the last quarter. Finally, State Street Corp bought a new position in shares of Tabula Rasa Healthcare during the fourth quarter valued at approximately $611,000. 25.42% of the stock is owned by institutional investors and hedge funds.
Tabula Rasa Healthcare (NASDAQ TRHC) traded down 1.88% during midday trading on Tuesday, reaching $13.54. The company’s stock had a trading volume of 130,687 shares. Tabula Rasa Healthcare has a 52 week low of $10.39 and a 52 week high of $16.85. The firm’s market cap is $233.13 million. The firm has a 50 day moving average price of $13.32 and a 200-day moving average price of $13.79.
Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its earnings results on Monday, May 1st. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.02. The business had revenue of $27.70 million for the quarter, compared to analysts’ expectations of $26 million. The company’s revenue for the quarter was up 37.1% on a year-over-year basis. On average, analysts forecast that Tabula Rasa Healthcare will post $0.41 earnings per share for the current fiscal year.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/tabula-rasa-healthcare-inc-trhc-receives-17-33-average-price-target-from-analysts/1916625.html
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.